Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Seifert-Held, T; Eberhard, K; Lechner, C; Macher, S; Hegen, H; Moser, T; Jacob, GB; Puttinger, G; Topakian, R; Guger, M; Kacar, E; Zoche, L; De Simoni, D; Seiser, A; Oberndorfer, S; Baumgartner, C; Struhal, W; Zimprich, F; Sellner, J; Deisenhammer, F; Enzinger, C; Reindl, M; Rauschka, H; Berger, T; Höftberger, R.
Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study.
Front Immunol. 2021; 12:641106-641106
Doi: 10.3389/fimmu.2021.641106
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Seifert-Held Thomas
- Co-Autor*innen der Med Uni Graz
- Eberhard Katharina
- Enzinger Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Prospective observations of functional recovery are lacking in patients with autoimmune encephalitis defined by antibodies against synaptic proteins and neuronal cell surface receptors. Adult patients with a diagnosis of autoimmune encephalitis were included into a prospective registry. At 3, 6 and 12 months of follow-up, the patients' modified Rankin Scale (mRS) was obtained. Patients were stratified into three groups according to their antibody (Ab) status: anti-NMDAR-Ab (n=12; group I), anti-LGI1/CASPR2-Ab (n=35; group II), and other antibodies (n=24; group III). A comparably higher proportion of patients in group I received plasma exchange/immunoadsorption and second line immunosuppressive treatments at baseline. A higher proportion of patients in group II presented with seizures. Group III mainly included patients with anti-GABABR-, anti-GAD65- and anti-GlyR-Ab. At baseline, one third of them had cancer. Patients in groups I and III had much higher median mRS scores at 3 months compared to patients in group II. A median mRS of 1 was found at all follow-up time points in group II. The different dynamics in the recovery of patients with certain autoimmune encephalitides have important implications for clinical trials. The high proportion of patients with significant disability at 3 months after diagnosis in groups I and III points to the need for improving treatment options. More distinct scores rather than the mRS are necessary to differentiate potential neurological improvements in patients with anti-LGI1-/CASPR2-encephalitis. Copyright © 2021 Seifert-Held, Eberhard, Lechner, Macher, Hegen, Moser, Jacob, Puttinger, Topakian, Guger, Kacar, Zoche, De Simoni, Seiser, Oberndorfer, Baumgartner, Struhal, Zimprich, Sellner, Deisenhammer, Enzinger, Reindl, Rauschka, Berger and Höftberger.
- Find related publications in this database (Keywords)
- autoimmune encephalitis
- anti-NMDAR-encephalitis
- anti-LGI1-encephalitis
- anti-CASPR2-encephalitis
- modified Rankin Scale